Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 17,010 as of Monday, Sept. 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 891 issues advancing vs. 2,107 declining with 158 unchanged. The Drugs industry currently sits down 2.0% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include NPS Pharmaceuticals ( NPSP), down 14.0%, Isis Pharmaceuticals ( ISIS), down 7.6%, Intercept Pharmaceuticals ( ICPT), down 5.8%, Jazz Pharmaceuticals ( JAZZ), down 4.9% and Pharmacyclics ( PCYC), down 3.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.57 (0.8%) to $73.87 on light volume. Thus far, 482,583 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $73.44-$73.96 after having opened the day at $73.76 as compared to the previous trading day's close of $73.30. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $93.4 billion and is part of the health care sector. Shares are up 23.5% year-to-date as of the close of trading on Friday. Currently there is 1 analyst who rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold. TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full AstraZeneca Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.